

primary studies - published RCT

## **Aerosolized lincovutide in adolescents (≥12 years) and adults with cystic fibrosis - a randomized trial.**

**Code:** PM32888826

**Year:** 2020 **Date:**

**Author:** Eber E

### **Study design (if review, criteria of inclusion for studies)**

SIMPLIFY (randomized, open-label study) substudy

### **Participants**

CF Patients ≥12 years of age.

### **Interventions**

Discontinuing hypertonic saline (HS) or dornase alfa (DA) vs continuation of each treatment

### **Outcome measures**

Change in lung function over a 6-week period. Authors used gamma scintigraphy to determine whether discontinuation of either HS or DA was associated with deterioration in the rate of in vivo mucociliary clearance (MCC)

### **Main results**

While no significant differences in MCC endpoints were associated with HS discontinuation, significant improvement in whole and peripheral lung MCC was observed after discontinuing DA.

### **Authors' conclusions**

These results suggest that pwCF on ETI with mild lung disease do not experience a subclinical deterioration in MCC that could later impact health outcomes after discontinuing HS, and in fact may benefit from improved MCC after stopping DA treatment.

<http://dx.doi.org/10.1016/j.jcf.2020.08.014>

### **See also**

J Cyst Fibros. 2020 Sep 1:S1569-1993(20)30830-4. doi: 10.1016/j.jcf.2020.08.014.

### **Keywords**

Adolescent; Child; Deoxyribonuclease; Drug Administration Schedule; Airway clearance drugs -expectorants- mucolytic- mucociliary-; hydration; Hypertonic Solutions; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological\_intervention; Recombinant Proteins; Respiratory System Agents; Dornase alpha; Pulmozyme; CFTR Modulators; Genetic Predisposition to Disease; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; elexacaftor; Trikafta; kaftrio;